Structural Insights into Emerging Inhibitors Targeting EGFR Mutations
Time: 12:00 pm
day: Day Two
Details:
- The structure of lazertinib allows for enhanced potency and mutant selectivity against EGFR T790M
- Next generation mutant EGFR C797S inhibitors bind the kinase domain through H-bonding with conserved catalytic residues
- Spanning ATP-allosteric EGFR inhibitors can be developed exhibiting unique kinase domain binding and mutant selectivity
